Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Is Estriol recalled?

Not under an active recall. Estriol was recalled 90 times in the past — all now closed. Most recent: Jun 10, 2022.

Most common reason: Cross-contamination (65 of these recalls)

Recalls are matched by product description. A recall usually affects specific lots, not every package of Estriol. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed. Checked against openFDA on Oct 10, 2026.

Estriol recalls on record

none so far in 2026; 90 on record, newest first
Class II · Moderate risk

Estriol 1mg/gm

Lack of Processing Controls: Insanitary conditions observed during recent FDA Inspection

Terminated cGMP deviation Wedgewood Village Pharmacy, LLC D-1186-2022
Class II · Moderate risk

Estriol 1mg/gm

Lack of Processing Controls: Insanitary conditions observed during recent FDA Inspection

Terminated cGMP deviation Wedgewood Village Pharmacy, LLC D-1185-2022
Class II · Moderate risk

Estriol 8 mg Capsule

Lack of Processing Controls (lack of assurance of conformity to specifications).

Terminated cGMP deviation MasterPharm LLC D-1421-2020
Class II · Moderate risk

Estriol 6 mg Capsule

Lack of Processing Controls (lack of assurance of conformity to specifications).

Terminated cGMP deviation MasterPharm LLC D-1420-2020
Class II · Moderate risk

Estriol USP Micronized 5 G

Failed impurities/ degradation specifications: Out of specification for organic impurities.

Terminated Impurity / degradation Triova Pharmaceuticals LLC NDC 71092-9977-02 D-1284-2020
Class II · Moderate risk

Estriol

Subpotent Drug: Supplier indicated assay results did not meet specifications.

Terminated Wrong potency / content Spectrum Laboratory Products D-0628-2020
Class II · Moderate risk

Estriol

Failed Impurities/Degradation Specifications: Additional testing found Out of Specification impurity test results.

Terminated Impurity / degradation Asclemed USA Inc. dba Enovachem Pharmaceuticals D-0652-2020
Class II · Moderate risk

Estriol

Failed Impurities/Degradation Specifications: Additional testing found Out of Specification impurity test results.

Terminated Impurity / degradation Asclemed USA Inc. dba Enovachem Pharmaceuticals D-0651-2020
Class II · Moderate risk

Estriol

Failed Impurities/Degradation Specifications: Additional testing found Out of Specification impurity test results.

Terminated Impurity / degradation Asclemed USA Inc. dba Enovachem Pharmaceuticals D-0650-2020
Class II · Moderate risk

Estriol

Failed Impurities/Degradation Specifications

Terminated Impurity / degradation Medisca, Inc. D-0622-2020
Class II · Moderate risk

Estriol USP

CGMP Deviations: Lack of stability data and controls to support the manufacturers assigned retest or expiration date in firm's container/closure system.

Terminated Stability / shelf life American Pharmaceutical Ingredients LLC NDC 58597-8048-2 D-0490-2018
Class II · Moderate risk

Estriol 0.1%

Labeling: Incorrect or Missing Lot and/or Exp Date: Beyond Use Date (BUD) exceed the BUD/EXP of at least one ingredient used to make final product.

Terminated Labeling / mix-up KRS Global Biotechnology, Inc D-0172-2018
Class II · Moderate risk

Bi-Est (Estriol/Estradiol)

Labeling: Incorrect or Missing Lot and/or Exp Date: Beyond Use Date (BUD) exceed the BUD/EXP of at least one ingredient used to make final product.

Terminated Labeling / mix-up KRS Global Biotechnology, Inc D-0168-2018
Class II · Moderate risk

Estriol

cGMP Deviations: lack of quality assurance at the API manufacturer.

Terminated cGMP deviation Fagron, Inc NDC 51552-1392-5 D-0079-2018
Class II · Moderate risk

Estriol

cGMP Deviations: lack of quality assurance at the API manufacturer.

Terminated cGMP deviation Fagron, Inc NDC 52372-9292-01 D-0791-2017
Class II · Moderate risk

Estriol

cGMP Deviations; manufacturer initiated recall of API product after deficiencies noted during a recent FDA inspection

Terminated cGMP deviation Medisca, Inc. NDC 38779-0732-03 D-0663-2017
Class II · Moderate risk

Estriol Micronized

cGMP Deviations; lack of quality assurance.

Terminated cGMP deviation Qinhuangdao Zizhu Pharmaceutical, Co. D-0656-2017
Class II · Moderate risk

ESTRIOL Gels

Penicillin Cross Contamination: potentially contaminated with penicillin

Terminated Cross-contamination Life Science Pharmacy Inc D-0495-2016
Class II · Moderate risk

ESTRIOL Creams

Penicillin Cross Contamination: potentially contaminated with penicillin

Terminated Cross-contamination Life Science Pharmacy Inc D-0494-2016